Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an ...

Japanese researchers have successfully eliminated the extra chromosome responsible for Down syndrome using CRISPR gene ...

A team at Kobe University has created a game-changing resource for autism research: 63 mouse embryonic stem cell lines, each ...

CRISPR Gene editing therapy is used for the first time in living humans with amazing results.

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

After 307 days at CHOP, KJ was dressed in what early studies suggest are the world’s smallest and cutest graduation ...

Crispr Therapeutics' current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles. Click ...